FDA Accepts GSK's Nucala for COPD Treatment
Ticker: GLAXF · Form: 6-K · Filed: Dec 9, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $7 billion |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-filing, drug-approval, respiratory
TL;DR
FDA accepted GSK's Nucala for COPD! Big win for respiratory treatments.
AI Summary
On December 9, 2024, GSK plc announced that the US Food and Drug Administration (FDA) has accepted its submission for Nucala (mepolizumab) to be used in the treatment of Chronic Obstructive Pulmonary Disease (COPD). This acceptance is based on data from the MATINEE study, which demonstrated a significant reduction in annualized exacerbation rates.
Why It Matters
This FDA acceptance could lead to a new treatment option for COPD patients, potentially improving their quality of life by reducing exacerbations.
Risk Assessment
Risk Level: low — This is a routine regulatory filing announcing the acceptance of a submission, not a significant financial event or unexpected development.
Key Numbers
- 001-15170 — Commission File Number (Identifies the specific SEC filing for GSK plc.)
Key Players & Entities
- GSK plc (company) — Registrant
- Nucala (company) — Drug Name
- mepolizumab (company) — Drug Generic Name
- US FDA (company) — Regulatory Agency
- COPD (company) — Medical Condition
- 001-15170 (dollar_amount) — Commission File Number
- December 9, 2024 (date) — Filing Date
FAQ
What is the specific indication GSK is seeking for Nucala in COPD?
The filing states the submission is for the use of Nucala (mepolizumab) in COPD, implying it's for exacerbation reduction.
What study supported this submission?
The submission is supported by data from the MATINEE study.
What was the outcome of the MATINEE study mentioned?
The MATINEE study showed a significant and clinically meaningful reduction in annualized exacerbation rates.
When was this report filed with the SEC?
This report was filed on December 9, 2024.
What is the primary business of GSK plc?
GSK plc is in the Pharmaceutical Preparations industry, SIC code 2834.
Filing Stats: 2,056 words · 8 min read · ~7 pages · Grade level 10.2 · Accepted 2024-12-09 07:59:38
Key Financial Figures
- $7 billion — costing the US healthcare system around $7 billion a year. 6,8,9       &#
Filing Documents
- a2715p.htm (6-K) — 61KB
- 0001654954-24-015262.txt ( ) — 62KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: December 09, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc